Objective: This study aimed to investigate the association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and NAFLD, as well as its relationship with hepatic steatosis and liver fibrosis, in a nationally representative sample of U.S. adults.Methods: This cross-sectional study analyzed data from 3,529 participants from the National Health and Nutrition Examination Survey in 2017–2020. Multivariable logistic regression and subgroup analyses were used to assess the association between NHHR and NAFLD. Multivariate linear regression was employed to evaluate the relationship between NHHR and hepatic steatosis (controlled attenuation parameter) and liver fibrosis (liver stiffness measurement). Nonlinear relationships were explored through fitted smoothing curves and threshold effect analysis. Receiver operating curve (ROC) analysis was performed to compare the diagnostic performance of NHHR with body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), and total cholesterol (TC).Results: The study included 3,529 participants (mean age: 51.34 years, 95% CI: 49.97, 52.72), with 53.53% male. NHHR showed a significant positive association with NAFLD after adjusting for confounders (OR: 1.33, 95% CI: 1.24, 1.42). Subgroup analysis indicated a stronger association in females and individuals with normal weight. A nonlinear relationship was identified, with a significant positive association below an inflection point of 4 (OR: 1.52, 95% CI: 1.38, 1.68). NHHR was positively associated with hepatic steatosis but not with liver fibrosis. For NAFLD diagnosis, NHHR achieved an area under the curve (AUC) of 0.66, outperforming TC (AUC = 0.51) but indicating lower accuracy than BMI (AUC = 0.77) and HDL-C (AUC = 0.68).Conclusion: NHHR is positively associated with NAFLD and hepatic steatosis in U.S. population, highlighting the important role of lipid control in the prevention and clinical management of NAFLD.
Objective: The study aims to explore the relationship between red blood cell (RBC) folate concentrations and accelerated aging.Methods: Data were derived from the National Health and Nutrition Examination Survey (NHANES) cycles of 2007–2010, including 8,944 participants aged ≥ 20 years. Phenotypic age acceleration (PhenoAgeAccel) was calculated using chronological age and 9 aging-related biomarkers. Multivariate linear regression and generalized additive models were used to analyze the relationship between RBC folate levels and PhenoAgeAccel. Smooth curve fitting was used to explore the potential non-linear relationship and threshold effect analysis was applied to examine inflection point.Results: The analysis revealed a U-shaped relationship between RBC folate levels and PhenoAgeAccel, with the inflection point at 732.9 ng/mL. The PhenoAgeAccel decreased by 0.0027 years per 1 ng/mL increase in RBC folate when RBC folate ≤ 732.9 ng/mL (β: −0.0027, 95% CI: −0.0051, −0.0002), and increased by 0.0058 years per 1 ng/mL increase in RBC folate when RBC folate > 732.9 ng/mL (β: 0.0058, 95% CI: 0.0026, 0.0090). Subgroup analysis indicated consistent associations across most demographic and health categories, except for a positive correlation in participants with cardiovascular diseases.Conclusion: There was a U-shaped association between RBC folate and accelerated aging among US adults.